One of the greatest challenges in urological oncology is renal cell carcinoma (RCC), which is the third leading cause of death in genitourinary cancers.
RCCs are highly vascularized and respond positively to antiangiogenic therapy. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the potential of ES-based antiangiogenic therapy to activate tumor-associated endothelial cells in metastatic RCC (mRCC). Balb/c-bearing Renca cells were treated with NIH/3T3-LendSN or, as a control, with NIH/3T3-LXSN cells. The T-cell subsets and lymphocyte populations of tumors, mediastinal lymph nodes and the spleen were assessed by flow cytometry. The expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was assessed by real-time PCR, flow cytometry and immunohistochemistry analysis. ES gene therapy led to an increase in the percentage of infiltrating CD4-interferon (IFN)-γ cells (P< 0.05), CD8-IFN-γ cells (P< 0.01) and CD49b-tumor necrosis factor-α cells (P< 0.01). In addition, ES therapy caused an increase at the mRNA level of ICAM-1 (1.4-fold; P< 0.01) and VCAM-1 (1.5-fold) (control vs treated group; P< 0.001). Through flow cytometry, we found a significant increase in the CD34/ICAM-1 cells (8.1-fold; P< 0.001) and CD34/VCAM-1 cells (1.6-fold; P< 0.05). ES gene therapy induced a significant increase in both T CD4 and CD8 cells in the lymph nodes and the spleen, suggesting that ES therapy may facilitate cell survival or clonal expansion. CD49b cells were also present in increased quantities in all of these organs. In this study, we demonstrate an antitumor inflammatory effect of ES in an mRCC model, and this effect is mediated by an increase in ICAM-1 and VCAM-1 expression in tumor-associated endothelial cells.
Written by:
Chaves KC, Peron JP, Chammas R, Turaça LT, Pesquero JB, Braga MS, Foguer K, Schor N, Bellini MH. Are you the author?
Department of Medicine, Nephrology Division, Federal University of São Paulo, Brazil.
Reference: Cancer Gene Ther. 2012 Aug;19(8):558-65.
doi: 10.1038/cgt.2012.32
PubMed Abstract
PMID: 22699868
UroToday.com Investigative Urology Section
